Antihyperlipidemic drugs

Similar documents
Antihyperlipidemic Drugs

Antihyperlipidemic Drugs

Anti Hyperlipidemic Drugs. Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia

ANTIHYPERLIPIDEMIA. Darmawan,dr.,M.Kes,Sp.PD

DYSLIPIDEMIA PHARMACOLOGY. University of Hawai i Hilo Pre- Nursing Program NURS 203 General Pharmacology Danita Narciso Pharm D

Introduction Hyperlipidemia hyperlipoproteinemia Primary hyperlipidemia (Familial) Secondary hyperlipidemia (Acquired)

PIEDMONT ACCESS TO HEALTH SERVICES, INC. Guidelines for Screening and Management of Dyslipidemia

MOLINA HEALTHCARE OF CALIFORNIA

A Review: Atherosclerosis & its treatment

Podcast (Video Recorded Lecture Series): Lipoprotein Metabolism and Lipid Therapy for the USMLE Step One Exam

Imbalances in lipid components

Hyperlipidemia. Prepared by : Muhannad Mohammed Supervisor professor : Dr. Ahmed Yahya Dallalbashi

ANTI-HYPERLIPIDEMIC AGENTS AND NSAIDS LECTURE 6

Management of Post-transplant hyperlipidemia

CLINICAL IMPORTANCE OF LIPOPROTEINS

Drug regulation of serum lipids

Lipid Lowering Drugs. Dr. Alia Shatanawi

Cholesterol. Medicines To Help You

B. Patient has not reached the percentage reduction goal with statin therapy

Drugs for Dyslipidemias

Financial Disclosures

Diseases & Conditions

Dyslipidemia. (Med-341)

VI.2 Elements for a public summary. VI.2.1 Overview of disease epidemiology

Copy right protected Page 1

Antihyperlipidemic Drugs Munir Gharaibeh, MD, PhD, MHPE

PART III: CONSUMER INFORMATION

Dyslipidemia. Team Members: Laila Mathkour, Khalid Aleedan, Bayan Al-Mugheerha, Fatima AlTassan

PATIENT INFORMATION. Medicine To Treat: C ardiac Diseases. Lipid-Lowering Medicines. Statins Fibrates Fat Binding Agents Nicotinic Acid Group

Full prescribing information is available to doctors and pharmacists on request.

Lecture 36 Dyslipidemia Therapeutics Barry LIPIDS:

Elements for a public summary

DISLIPIDEMIA. Dharma Lindarto. Div: Endokrinologi-Metabolik. Departemen Ilmu Penyakit Dalam FK USU/RSUP. H Adam Malik Medan

Rosuvastatin 5 mg, 10 mg and 20 mg Tablet

Lipid Therapy: Statins and Beyond. Ivan Anderson, MD RIHVH Cardiology

Non-Statin Lipid-Lowering Agents M Holler - Last updated: 10/2016

PHARMACOKINETICS ABSORPTION

There is some evidence to suggest that the half-life of felbamate may be prolonged by gabapentin.

In May 2001, the National Cholesterol. Effective Management of Patients With Dyslipidemia REPORT. Robert J. Lipsy, PharmD

CE Prn. Pharmacy Continuing Education from WF Professional Associates ABOUT WFPA LESSONS TOPICS ORDER CONTACT MCA EXAM REVIEWS

Lipid- Lowering Medica0ons. Drugs for Med Students Presented by Eric Campbell & Jen Chen

Fibrate and cardiovascular disease: Evident from meta-analysis. Thongchai Pratipanawatr

High ( 50%) Restrictions mg 20-40mg PA; TS ⱡ 15 ⱡ

FORTH VALLEY. LIPID LOWERING GUIDELINE v5 2016

Lipid Guidelines Who, What, and How Low. Anita Ralstin, MS, CNP Next Step Health Consultant, LLC New Mexico Heart Institute

CHOLESTAGEL 625 mg Genzyme

Eveness Rosuvastatin. Each tablet contains 5mg, 10mg, 20mg, or 40 mg of rosuvastatin (as calcium salt)

Royal Wolverhampton Hospital Adult Lipid Lowering Therapy Guidelines Lipid Lowering Therapy for the Prevention of Cardiovascular Disease

A mong the 20 leading prescription

Approach to Dyslipidemia among diabetic patients

T REV 21. See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling. Revised: 07/2009

Hypertriglyceridemia. Ara Metjian, M.D. Resident s Report 20 December 2002

> 130 > 130 (10-20% risk) <130 >160 (<10% risk) 0-1 Risk Factors <160 >160 >190

If yes, continue to #2. If no, do not approve. DENIAL TEXT: See the initial denial text at the end of the guideline.

Zetia (Ezetimibe) Drug Monograph. Clinical clerkship Students (Week 1)

Coronary heart disease is the leading cause of death in

READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION LIPIDIL EZ. fenofibrate, NanoCrystal formulation tablets

Doctor discussion guide:

March 2005 Current Trends in Treating Elevated Cholesterol H01

1.* Dosage. A. Adults

RISK FACTORS AND DRUG TO STATIN-INDUCED MYOPATHY

Doctor discussion guide:

Unit IV Problem 3 Biochemistry: Cholesterol Metabolism and Lipoproteins

CHOLESTEROL REDUCING MEDICATIONS. Five Main Categories. 1. Statins 2. Fibrates 3. Resins 4. Niacin 5. Cholesterol absorption inhibitor

Lipids & Hypertension Update

International Journal of Chemistry and Pharmaceutical Sciences

LESSON ASSIGNMENT. After you finish this lesson you should be able to:

Cholesterol metabolism. Function Biosynthesis Transport in the organism Hypercholesterolemia

REACH Risk Evaluation to Achieve Cardiovascular Health

Pharmacology: Hyperlipidemia PC PHPP 515 (IT-I) Fall JACOBS Monday, Oct. 20 4:00 4:50 PM

Rhabdomyolysis from the Combination of a Statin and Gemfibrozil: An Uncommon But Serious Adverse Reaction

In the Know: Canadian Guidelines for Dyslipidemia, 2003

Hypertriglyceridemia: Why, When, and How to Treat. Gregory Cohn, MD, FNLA, FASPC

ROSULIP. Composition Rosulip 10 mg Each tablet contains 10 mg Rosuvastatin (as calcium).

Classification. Etiology

Advicor (niacin extended-release/lovastatin tablets)

Kavita Sharma, MD Diplomate, American Board of Clinical Lipidology

Advicor. This information is intended for U.S. residents only. (niacin extended-release/lovastatin tablets) only

May 2003 Lipid Management H01 HAVE YOU RECENTLY MOVED? PLEASE NOTIFY US.

Pharmacology Challenges: Managing Statin Myalgia

Major recommendations for statin therapy for ASCVD prevention

TABLETS ZOCOR (SIMVASTATIN)

PACKAGE INSERT TEMPLATE FOR ATORVASTATIN TABLET. Brand or Product Name [Product name] Tablet 80mg

Lipid Goals: Update on their Status

Lipoprotein Formation, Structure and Metabolism: Cholesterol Balance and the Regulation of Plasma Lipid Levels

Original paper. Abstract. Abdullah S. Asia 1*, Al-Mahdi A. Modar 2, Hadi M. Ali 3

ANSC/NUTR 618 LIPIDS & LIPID METABOLISM The LDL Receptor, LDL Uptake, and the Free Cholesterol Pool

Dyslipidemia and HIV NORTHWEST AIDS EDUCATION AND TRAINING CENTER

ATP III (Adult Treatment Panel III) CLASSIFICATION C IN ADULTS

Treating dyslipidemia

Dyslipidemia. Pharmacological Options and Considerations for Management

CRESTOR 10 mg, 20 mg, 40 mg Film Coated Tablets

AUSTRALIAN PI BLOOMS THE CHEMISTS-EZETIMIBE TABLETS (EZETIMIBE) 2 AND 3 QUALITATIVE AND QUANTITATIVE COMPOSITION AND PHARMACEUTICAL FORM

Colesevelam hydrochloride: a specifically engineered bile acid sequestrant

Frequency of Simvastatin Prescriptions With Potentially Interacting Medications in a Veterans Affairs Health Care System

PRODUCT MONOGRAPH. fenofibrate, micronized formulation Capsules (200 mg) Lipid Metabolism Regulator

MMBS, MMED (Path),MAACB, MACTM, MACRRM

Nicotinic Acid Nicotinic Acid

Update on the Treatment of Hyperlipidemia

Tuesday, October 18 3:30 p.m. 5:30 p.m. Convention Center: Rooms 315 & 316

Transcription:

Antihyperlipidemic drugs The clinically important lipoproteins are LDL low density lipoprotein, VLDL very low density lipoprotein, HDL high density lipoprotein. Hyperlipidemia may caused 1. by individual lifestyle (lack of exercise and high consumption of fatty acid). 2. single inherited gene defect in lipoprotein metabolism 3. more commonly, combination of genetics and lifestyle factors. The incidence of the heart failure is correlated with elevated levels of low density lipoproteins (LDL) cholesterol, and triglycerides with low level of highdensity lipoprotein cholesterol (HDL).

Antihyperlipidemic drugs Antihyperlipidimic drugs must be taken indefinitely, when terminated plasma levels return to pretreatments levels. Antihyperlipidimic drugs target the problem with complimentary strategies, including: 1. decrease production of the lipoproteins carriers of cholesterol and triglyceride. 2. others increase the degradation of lipoproteins. 3. decrease cholesterol absorption or directly increase cholesterol removal from the body. These agents may used as a singly or in combination.

Hyperlipoproteinemia Labs description Type I Type IIa Type IIb Familial hyperchylomicronemia Familial hypercholesterolemia Combined hyperlipidemia Elevated Chylomicrons and VLDL Elevated LDL only Elevated LDL and VLDL and Triglycerides Type III Familial Dysbetalipoproteinemia Increased IDL Type IV Familial Hyperlipemia Increased VLDL Type V Endogenous Hypertriglyceridemia Increased VLDL and Chylomicrons

Statins These agents include Lovastatin, pravastatin, simvastatin, fluvastatin, Atorvastatin, rosuvastatin Cerivastatin Mechanism of action (1) They are 3-Hydroxy-3-methylglutaryl coenzyme A reductase (HMG CoA) inhibitors. This enzyme facilitate rate-limiting-step in the cholesterol synthesis and inhibiting this step will stop cholesterol synthesis. (2) Increase in LDL receptors: Depletion of intracellular cholesterol causes the cell to increase the number of specific cell-surface LDL receptors that can bind and internalize circulating LDLs. Thus the end result is a reduction in plasma cholesterol.

Statins Side effects: -Biochemical abnormalities in liver function (evaluate liver function is needed) -Myopathy and rhabdomyolysis (disintegration or dissolution of muscle). These agents are contraindicated during pregnancy and in nursing mothers. They also should not be used in children and teenagers.

Statins interaction The catabolism of lovastatin, simvastatin, and atorvastatin proceeds chiefly through CYP3A4, whereas that of fluvastatin and rosuvastatin is mediated by CYP2C9. Pravastatin is catabolized through other pathways, including sulfation. Concomitant use of reductase inhibitors with amiodarone or verapamil also causes an increased risk of myopathy.

The 3A4-dependent reductase inhibitors include the macrolide antibiotics, cyclosporine, ketoconazole and its congeners, HIVprotease inhibitors, tacrolimus, nefazodone, fibrates, and others. Conversely, drugs such as phenytoin, griseofulvin, barbiturates, rifampin, and thiazolidinediones increase expression of CYP3A4 and can reduce the plasma concentrations of the 3A4-dependent reductase inhibitors. Inhibitors of CYP2C9 such as ketoconazole and its congeners, metronidazole, sulfinpyrazone, amiodarone, and cimetidine may increase plasma levels of fluvastatin and rosuvastatin. Plasma levels of lovastatin, simvastatin, and atorvastatin may be elevated in patients ingesting more than 1 liter of grapefruit juice daily.

Niacin (vitamin B 3 ) Mechanism of Action: strongly inhibits lipolysis in adipose tissue the primary producer of circulating free fatty acids, both plasma triacylglycerol (in VLDL) and cholesterol (in VLDL and LDL) are lowered Niacin is the most effective agent in increase the HDL (the good cholesterol carrier). it is used in type IIb and IV hyperlipoproteinemia, in which both VLDL and LDL are elevated. Also to treat other severe hypercholestrolemias

Niacin Adverse effects: Cutaneous flushing, burning and itching, GI irritation, nausea and vomiting. Peptic ulcer activation, elevation of liver enzymes, hyperglycemia and hyperuricemia.

Fibrates Fenofibrate and Gemfibrozil, Bezafibrate are derivatives of fibric acid lower serum level of LDL cholesterol, triglyceride and increase the HDL. MOA: Peroxisome proliferator activated receptors (PPARs) are a nuclear receptors that regulate lipid metabolism. Fibrat triacylglyceroles binding to these receptors result in reduction of concentration by increasing the expression of lipoprotien lipase. They are used in the treatment of hypertriglycerolemias.

Adverse effect Fibrates a. The most common adverse effects are mild gastrointestinal disturbances. b. Lithiasis: Because these drugs increase biliary cholesterol excretion, there is a predisposition to the formation of gallstones. d. Myositis (inflammation of a voluntary muscle) can occur. Fibrates compete with the coumarin anticoagulants for binding sites on plasma proteins.

Bile acid-binding resins Cholestyramine and colestipol have significant LDL cholesterol lowering effect, although the benefit is less than those observed with statins. These agents are resins that bind bile acid in the intestine, forming insoluble complexes that will excreted in the feces. Lowering bile acid level will trigger the conversion of cholesterol into bile acid and the end result will be a reduction in the cholesterol concentrations. Therapeutic uses: The bile acid binding resins are the drugs of choice (often in combination with diet or niacin) in treating Type lla.

Bile acid-binding resins The most common side effect are gastrointestinal disturbances such as constipation and nausea. At high doses they impair the absorption of fat soluble vitamins (A,D,E, and K). These agents interact with the absorption of many drugs, for example, Tetracycline, Digoxin, Warfarin, Aspirin. Therefore, drugs should be taken at least 1 to 6 hr after.

Cholestrole absorption inhbitors Ezetimibe selectively inhibit intestinal absorption of dietary and biliary cholesterol in the small intestine, resulting in an increase in the clearance of cholesterol from the blood. Common adverse are headache and/or diarrhea.

Strategy for Controlling Hyperlipidemia Diet Ezetimibe Serum Cholesterol Biosynthesis HMG CoA reductase STATINS LDL-R Cellular Cholesterol 21 Bile Acids Intestine Feces Re-absorption BILE ACID SEQUESTRANTS MEDC 603 Steroids Lipoprotein catabolism Conversion to hormones within cells or storage as granules FIBRATES 11/24/2013